GenWand™ Double-Stranded DNA (dsDNA) service for T-cell engineering

GenScript USA Inc., a global leader in life science research tools and services, recently announced the launch of the GenWand™ Double-Stranded DNA (dsDNA) service for the production of CRISPR knock-in homology-directed repair (HDR) templates in T cell engineering.

Closed-end dsDNA allows researchers to conduct gene knock-in with greater efficiency and lower toxicity than conventional PCR methods and is the perfect solution for large-scale screening and scale-up in cell and gene therapy.

We continue to believe that non-viral vector delivery has clear advantages - including safety - in CRISPR/Cas applications for gene and cell therapy. Our GenWand closed-end DNA service offers better performance and scalability to researchers, and represents an important expansion of our portfolio of services for gene and cell therapy."

Ray Chen, PhD, President, Life Science Group, GenScript

GenScript's GenWand dsDNA service produces covalently closed-end linear DNA to help enhance dsDNA stability by restricting digestion of the dsDNA by endonucleases once entering cells. It also reduces the risk of non-homologous end joining and boosts the accuracy of knock-in when applying CRISPR homology-directed repair machinery.

Manufactured using a proprietary production process, GenScript's dsDNA is available in 2-10 kb sequences from micrograms to grams. Varying grade qualities are available from research grade to basic GMP.

This new service complements an expanding portfolio of offerings for CRISPR/Cas genome editing, including the GenExact™ ssDNA Service and Phase Appropriate GMPsgRNA through its CRISPR Synthetic Guide RNA Services.

In collaboration with the University of California, San Francisco, GenScript has helped deliver around 2.3 Kb ssDNA for T cell engineering with non-viral genome targeting utilizing long DNA sequences.

Each year the company produces over 10,000 sgRNA, which it delivers to clients around the world. GenScript has also manufactured over 30 phase-appropriate GMP sgRNA batches for biopharma clients in China.

As a global leader in gene synthesis, GenScript is committed to offering a one-stop-shop to customers developing new immunotherapies to fight cancer. "We are continually expanding our portfolio of innovative new products and services in this field and expect to support additional projects at the basic GMP level for investigational new drug applications and early-stage clinical trials."

Ray Chen, PhD, President, Life Science Group, GenScript

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global leading biotechnology group.

Through the application of its leading gene synthesis technology, GenScript has been able to develop four major platforms, including the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, the global cell therapy platform, and the industrial synthesis product platform.

GenScript was founded in New Jersey, United States, in 2002 and was listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation covers over 100 global territories, with legal entities in the USA, mainland China, Hong Kong, Japan, Singapore, the Netherlands, and Ireland.

GenScript offers convenient and premium products and services for over 100,000 customers.

GenScript has ownership of numerous intellectual property rights and technical secrets, including over 100 patents and more than 270 patent applications. As of December 31st, 2020, GenScript's products and services have been cited by 52,500 peer-reviewed journal articles worldwide. For additional information, visit:

About GenScript

Genscript is the world’s leading biotech company providing life sciences services and products. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading biotech company specializing in fundamental life sciences research and early-phase drug discovery services. As of 2018, more than 30,000 peer-reviewed journal articles cited GenScript’s services and products, making GenScript the most frequently cited biotech company in the world.

After almost two decades of fast growth in developing biological reagents, the company has expanded its business into immunotherapy, CDMO, laboratory equipment, and microbial industry to further fulfill its mission in making people and nature healthier through biotechnology.

Founded in 2002 in New Jersey, United States, GenScript serves as a partner for researchers in basic life sciences, translational and biomedical fields as well as early-stage drug development.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Sep 8, 2022 at 5:23 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    GenScript. (2022, September 08). GenWand™ Double-Stranded DNA (dsDNA) service for T-cell engineering. News-Medical. Retrieved on July 23, 2024 from

  • MLA

    GenScript. "GenWand™ Double-Stranded DNA (dsDNA) service for T-cell engineering". News-Medical. 23 July 2024. <>.

  • Chicago

    GenScript. "GenWand™ Double-Stranded DNA (dsDNA) service for T-cell engineering". News-Medical. (accessed July 23, 2024).

  • Harvard

    GenScript. 2022. GenWand™ Double-Stranded DNA (dsDNA) service for T-cell engineering. News-Medical, viewed 23 July 2024,

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.